Ressourcen

Finden Sie ein teilnehmendes Zentrum für die klinische Studie AIRFLOW-3 oder holen Sie sich die neuesten Nachrichten und Medien-Updates über Nuvaira.

Eine Klinik finden

Finden Sie eine Klinik in Ihrer Nähe, die die Behandlung mit dem dNerva-Lungendenervierungssystem im Rahmen der klinischen Studie AIRFLOW-3 anbietet.

Behandlungszentren in Europa

Österreich
Klinik Floridsdorf
Vienna, Österreich
Frankreich
Hopital de la Cavale Blanche
Brest, Frankreich
CHU de Grenoble
Grenoble, Frankreich
Hopital Arnaud de Villeneuve
Montpellier, Frankreich
Hopital Pasteur
Nice, Frankreich
Claude-Bernard – Hopital Bichat
Paris, Frankreich
CHU de Reims
Reims, Frankreich
Nouvel Hopital Civil
Straßburg, Frankreich
Hopital Larrey
Toulouse, Frankreich
Deutschland
Thoraxklinik Universitätsklinikum Heidelberg
Heidelberg, Deutschland
Niederlande
University Medical Center Groningen
Groningen, Niederlande
Amsterdam UMC
Amsterdam, Niederlande
Vereinigtes Königreich
Royal Brompton Hospital
London, Vereinigtes Königreich

Behandlungszentren in den Vereinigte Staaten von Amerika

Alabama
University of Alabama Lung Health Center
Birmingham, Alabama
Arizona
Honor Health
Birmingham, Alabama
California
UC Davis Health
Sacramento, CA
Harbor-UCLA Medical Center
Torrance, CA
Florida
Ascension St. Vincent’s
Jacksonville, FL
Illinois
The University of Chicago Medicine
Chicago, IL
AMITA Health Alexian Brothers Medical Center Elk Grove Village
Elk Grove Village, IL
Kentucky
University of Louisville Health
Louisville, KY
Ohio
The Ohio State University Wexner Medical Center
Columbus, OH
Michigan
University of Michigan Health
Ann Arbor, MI
Spectrum Health
Grand Rapids, MI
Massachusetts
Beth Israel Lahey Health
Burlington, MA
Missouri
Washington University Medical Center
St. Louis, MO
North Carolina
Duke University Medical Center
Durham, NC
Pennsylvania
Temple Health Lung Center
Philadelphia, PA
University of Pittsburgh Medical Center
Pittsburgh, PA
South Carolina
Medical University of South Carolina
Charleston, SC
Texas
Houston Methodist Hospital
Houston, TX
St. David’s Medical Center
Georgetown, TX

Nehmen Sie mit uns Kontakt auf, um weitere Informationen über das Verweisen von Patienten zu finden

Nachrichten und Medien

Jan 25, 2022

200th Treatment Milestone for AIRFLOW-3 COPD Trial

300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…

Aug 11, 2021

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone 100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, August…

Nov 23, 2020

Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a…

Jun 08, 2020

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…

Feb 04, 2020

Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…

Aug 19, 2019

Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes

AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…

Literatur

Discover if your patient may be a good fit for the AIRFLOW-3 clinical trial